Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis
GLOW Peptide Regulatory Status As of June 2026, none of the three GLOW compounds (BPC-157, TB-500, GHK-Cu) are FDA-approved for injectable human use
**Lot certified by HPLC certificate of analysis exceeding 99%, mass spectrometry confirming theoretical molecular weight (BPC-157: 1419.53 Da / TB-500 fragment: supplier-dependent, full thymosin beta-4: 4963 Da), cold chain maintained from synthesis to delivery.** Unique dual-lyophilized vial, two-minute reconstitution, aliquoting supported to extend functional shelf life
has consultancy agreements with Novartis and received honoraria for advisory boards with Novartis, Galderma, Napp, Sanofi, Eli Lilly and Janssen, which funded a recent Cardiff University Dermatology Life Quality Index (DLQI) research project, in which he is a joint inventor and receives royalties